REG - Indivior PLC - Notice of Q1 Results

IndiviorAnnouncement

07/04/2022 10:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220407:nRSG6315Ha&default-theme=true

RNS Number : 6315H  Indivior PLC  07 April 2022

 

 

 

Indivior to Announce Q1 2022 Results and Host Webcast on April 28(th)

Slough, UK, and Richmond, VA, April 7, 2022 - Indivior PLC (LON: INDV) today
announced that it will release its Q1 2022 results on April 28(th) at 12:00
GMT (7:00 a.m. U.S. Eastern). The results will be available via the London
Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section
of the company's website at www.indivior.com (http://www.indivior.com) .

Mark Crossley, Chief Executive Officer, and other members of Indivior's
leadership team will host a presentation via live webcast at 13:00 GMT (8:00
a.m. U.S. Eastern) on April 28(th).

Access to the Live Webcast Presentation

The webcast event and materials can be accessed on the "Investors" section of
the company's website at www.indivior.com (http://www.indivior.com) before the
event begins.

The webcast link is https://edge.media-server.com/mmc/p/ogy6nn93
(https://edge.media-server.com/mmc/p/ogy6nn93) .

Participants may access the presentation telephonically:

·    US participants 1-646-741-3167

·    International participants +44 (0) 2071-928338

 

Please reference confirmation ID 6687840. A replay of the presentation will be
available at www.indivior.com (http://www.indivior.com) .

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders (SUD) and
serious mental illnesses. Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from
a global human crisis to a recognized and treated chronic disease. Building on
its global portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category and
potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs more than 900
individuals globally and its portfolio of products is available in over 40
countries worldwide. Visit www.indivior.com
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.indivior.com%2F&data=04%7C01%7Cjason.thompson%40Indivior.com%7C50524c1bfa284722f7ee08da13118474%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C637843263192018647%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=XV57BWLOjOnGhAQJWI0WKEK4%2FXf0M9QcOEiYwwerqho%3D&reserved=0)
to learn more. Connect with Indivior on LinkedIn by visiting
www.linkedin.com/company/indivior
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Findivior&data=04%7C01%7Cjason.thompson%40Indivior.com%7C50524c1bfa284722f7ee08da13118474%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C637843263192018647%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=ztGNJPoRRJvCmxgR2tqSP1oJuDdNpAGH7hPFUtuOHcA%3D&reserved=0)
.

 

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or jason.thompson@indivior.com
(mailto:jason.thompson@indivior.com)

 

Tim Owens

Director, Investor Relations

Tel: 804-263-3978 or timothy.owens@indivior.com
(mailto:timothy.owens@indivior.com)

 

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBKOBBFBKKDQK